Adult genitourinary sarcoma: The era of optional chemotherapeutic agents for soft tissue sarcoma.
adult
drug therapy
sarcoma
survival
urogenital system
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
01
04
2020
accepted:
27
09
2020
pubmed:
11
11
2020
medline:
28
4
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
To report our institutional experience with treatment of primary genitourinary soft tissue sarcoma. We retrospectively reviewed the medical records of adult soft tissue sarcoma patients treated between March 2005 and May 2019. The primary tumor sites included the prostate, kidney, urinary bladder and the paratesticular structures. A total of 19 patients - 16 men (84%) and three women (16%) - were enrolled in the study. The median age was 41 years (range 20-79 years). The most common primary site was the prostate (in eight patients; 42%), and prostatic sarcoma patients were younger than patients with sarcomas of other origins. The most common histological subtype was leiomyosarcoma (in five patients; 26%). The overall survival rates after 1, 3 and 5 years were 61.5%, 34.4% and 25.8%, respectively. The median survival time was 20.7 months (95% confidence interval 5.9-35.5 months). Univariate analysis showed that an absence of metastasis at diagnosis and complete surgical resection were predictive of favorable survival. In the chemotherapy group, the objective response rate was 20.5%. Pazopanib was administered to nine patients in the late-line setting, and the objective response rate was 11.1%; six grade ≥3 adverse events were observed in three patients. Inoperable metastatic genitourinary soft tissue sarcoma remains difficult to treat, as previously reported. Further investigation on this malignancy, including optimization of currently available antitumor drugs and the development of novel therapeutic agents, is required.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-97Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Japanese Urological Association.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 2017; 67: 7-30.
Ogura K, Higashi T, Kawai A. Statistics of soft-tissue sarcoma in Japan: report from the Bone and Soft Tissue Tumor Registry in Japan. J. Orthop. Sci. 2017; 22: 755-64.
Stojadinovic A, Leung DH, Allen P et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J. Clin. Oncol. 2002; 20: 4344-52.
Russo P, Brady MS, Conlon K et al. Adult urological sarcoma. J. Urol. 1992; 147: 1032-7.
Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Paediatr. Drugs 2002; 4: 21-8.
Sexton WJ, Lance RE, Reyes AO et al. Adult prostate sarcoma: the M. D. Anderson Cancer Center experience. J. Urol. 2001; 166: 521-5.
Musser JE, Assel M, Mashni JW et al. Adult prostate sarcoma: the Memorial Sloan Kettering experience. Urology 2014; 84: 624-8.
De Bari B, Stish B, Ball MW et al. Adult prostatic sarcoma: a contemporary multicenter Rare Cancer Network study. Prostate 2017; 77: 1160-6.
Spiess PE, Kassouf W, Steinberg JR et al. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol. Oncol. 2007; 25: 38-45.
Wang X, Xu R, Yan L et al. Adult renal sarcoma: clinical features and survival in a series of patients treated at a high-volume institution. Urology 2011; 77: 836-41.
Khoubehi B, Mishra V, Ali M et al. Adult paratesticular tumors. BJU Int. 2002; 90: 707-15.
Dotan ZA, Tal R, Golijanin D et al. Adult genitourinary sarcoma: The 25-year Memorial Sloan-Kettering experience. J. Urol. 2006; 176: 2033-9.
Mondaini N, Palli D, Saieva C et al. Clinical characteristics and overall survival in genitourinary sarcomas treated with curative intent: a multicenter study. Eur. Urol. 2005; 47: 468-73.
Izumi K, Mizokami A, Sugimoto K et al. Role of surgical resection in adult urological soft tissue sarcoma: 25-year experience. Urol. Int. 2010; 84: 309-14.
Wang X, Tu X, Tan P et al. Adult genitourinary sarcoma: clinical characteristics and survival in a series of patients treated at a high-volume institution. Int. J. Urol. 2017; 24: 425-31.
Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113: 573-61.
Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J. Clin. Oncol. 2007; 25: 2755-63.
van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-86.
Kawai A, Araki N, Sugiura H et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015; 16: 406-16.
Schöffski P, Chawla S, Maki RG et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387: 1629-37.
Epstein JI, Egevad L, Humphrey PA et al. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am. J. Surg. Pathol. 2014; 38: e6-19.
Tap WD, Wagner AJ, Papai Z et al. ANNOUNCE: a randomized, placebo (PBO)-controlled, double blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). Presented at: 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4; Chicago, IL. Abstract LBA3.
Kawai A, Yonemori K, Takahashi S et al. Systemic therapy for soft tissue sarcoma: protocols for the optimal use of pazopanib, trabectedin, and eribulin. Adv. Ther. 2017; 34: 1556-71.
Kobayashi E, Naito Y, Asano N et al. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn. J. Clin. Oncol. 2019; pii: hyz096.
Kawaguchi K, Nakano K, Urasaki T et al. Retrospective analysis of trabectedin therapy for soft tissue sarcoma. In Vivo 2019; 33: 1609-14.
Nakano K, Takahashi S. Current molecular targeted therapies for bone and soft tissue sarcomas. Int. J. Mol. Sci. 2018; 19: E739.
Butrynski JE, D’Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 2010; 363: 1727-33.
Kummar S, Allen D, Monks A et al. Cediranib for metastatic alveolar soft part sarcoma. J. Clin. Oncol. 2013; 31: 2296-302.
O’Sullivan Coyne G, Sharon E, Moore N et al.Phase 2 study of atezolizumab in patients with alveolar soft part sarcoma. Presented at: CTOS 2018 annual meeting, Rome, Italy: November 14-17. Paper 021.
Ogura K, Hosoda F, Arai Y et al. Integrated genetic and epigenetic analysis of myxofibrosarcoma. Nat. Commun. 2018; 9: 2765.